Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2013

View Archived Issues

Identification of a unique series of small-molecule antiproliferative chromatin adaptor inhibitors

Evaluation of antibody-based delivery of IL-2 for the treatment of blood cancers

A priming dendritic cell-based vaccine confers broad-spectrum antitumor immunity

Results of HIV-CORE002 trial of HIVconsv vaccines reported

Discovery of novel EP4 agonists reported by Cayman Chemical Company, Myometrics

Constellation Pharmaceuticals discovers novel EZH2 inhibitors for cancer

Kadmon planning phase II trials of KD-025 in three indications

Helix BioPharma completes interim review of phase I/II study of L-DOS47 in lung cancer

Synthetic Biologics begins manufacture of SYN-004 for evaluation against C. difficile infections

Radiotherapy/imaging with trimeric GEBP11 peptide assessed in gastric cancer

MED12 expression as a prognostic marker in NSCLC

Johnson & Johnson reviews third quarter 2013

Lytix Biopharma receives clearance to conduct phase I study of LTX-315

FDA approves Novoeight for use in adults and children with hemophilia A

Esteve reports data from phase II study of E-58425 in acute pain

FDA agrees with Omeros' pediatric study plan for OMS-302

Hanmi Pharmaceutical advances new biological drug for diabetes to phase IIb trials

Phase III alirocumab results show efficacy superior to ezetimibe

RedHill's combination therapy achieves 80% remission in pediatric patients with Crohn's disease

Dynavax reveals design of phase III trial of hepatitis B vaccine

FDA committee votes against approval of Vascepa

FDA extends review of AMAG's sNDA to expand indication for Feraheme

Scientists at EnVivo Pharmaceuticals patent novel PDE9A inhibitors

Taiho Pharmaceutical synthesizes new vasopressin receptor antagonists

New JCV neutralizing antibodies discovered at Biogen Idec

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...